Sabina Maria Bruno
Overview
Explore the profile of Sabina Maria Bruno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruno S, Blacona G, Lo Cicero S, Castelli G, Virgulti M, Testino G, et al.
Genes (Basel)
. 2023 Sep;
14(9).
PMID: 37761921
In the precision medicine era of cystic fibrosis (CF), therapeutic interventions, by the so-called modulators, target the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The levels of targetable CFTR proteins...
2.
Lo Cicero S, Castelli G, Blacona G, Bruno S, Sette G, Pigliucci R, et al.
Respir Res
. 2023 Sep;
24(1):228.
PMID: 37742000
No abstract available.
3.
Lo Cicero S, Castelli G, Blacona G, Bruno S, Sette G, Pigliucci R, et al.
Respir Res
. 2023 Sep;
24(1):217.
PMID: 37674160
Cystic fibrosis (CF) is caused by defects of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR-modulating drugs may overcome specific defects, such as the case of Trikafta, which is...
4.
Conflitti A, Cicolani G, Buonacquisto A, Pallotti F, Faja F, Bianchini S, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36674527
The evaluation of morpho-functional sperm characteristics alone is not enough to explain infertility or to predict the outcome of Assisted Reproductive Technologies (ART): more sensitive diagnostic tools are needed in...
5.
Terracina S, Ferraguti G, Petrella C, Bruno S, Blacona G, Di Certo M, et al.
Curr Cancer Drug Targets
. 2022 Aug;
23(2):87-102.
PMID: 35975845
Evidence shows that there is a synergistic, bidirectional association between cancer and aging with many shared traits. Age itself is a risk factor for the onset of most cancers, while...
6.
Sette G, Lo Cicero S, Blacona G, Pierandrei S, Bruno S, Salvati V, et al.
Eur Respir J
. 2021 Aug;
58(6).
PMID: 34413153
Question: Cystic fibrosis (CF) is due to pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent improvements have enabled pharmacological therapy aiming at restoring mutated CFTR expression...
7.
Pierandrei S, Truglio G, Ceci F, Del Porto P, Bruno S, Castellani S, et al.
Int J Mol Sci
. 2021 Apr;
22(7).
PMID: 33916525
The interplay between the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC) in respiratory epithelia has a crucial role in the pathogenesis of cystic fibrosis (CF)....
8.
Sterrantino M, Fuso A, Pierandrei S, Bruno S, Testino G, Cimino G, et al.
Diagnostics (Basel)
. 2021 Jan;
11(2).
PMID: 33504063
Genetic analysis in cystic fibrosis (CF) is a difficult task. Within the many causes of variability and uncertainty, a major determinant is poor knowledge of the functional effect of most...
9.
Terlizzi V, Padoan R, Claut L, Colombo C, Fabrizzi B, Lucarelli M, et al.
Diagnostics (Basel)
. 2020 Dec;
10(12).
PMID: 33322690
Background: There are no predictive factors of evolution of cystic fibrosis (CF) screen positive inconclusive diagnosis subjects (CFSPIDs). Aim: to define the role of the second variant as a predictive...
10.
Lucarelli M, Porcaro L, Biffignandi A, Costantino L, Giannone V, Alberti L, et al.
J Mol Diagn
. 2017 Jul;
19(5):788-800.
PMID: 28736296
Searching for mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) is a key step in the diagnosis of and neonatal and carrier screening for cystic fibrosis (CF), and...